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ABSTRACT 
 
BACKGROUND: Stress fractures are one of the more severe overuse injuries 
and occur more frequently in women than men. Location and severity of stress 
fractures vary according to the sport and intensity of physical activity and most 
commonly involve the lower extremities. The treatment period may extend 
beyond 12 weeks based on the severity of the stress fracture and physical 
activity of the patient. Although data are sparse, there is an evolving interest in 
using systemic medical interventions to potentially improve or accelerate stress 
fracture repair. Intermittent administration of human recombinant parathyroid 
hormone (PTH) (1-34) (Teriparatide) is a FDA-approved anabolic treatment used 
to treat osteoporosis in men and women and reduce fracture risk in 
postmenopausal women. Although there may be potential benefits of systemic 
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teriparatide therapy to hasten the healing of fractures, there only a few 
randomized, controlled studies at present. 
OBJECTIVES: To determine in this randomized, placebo-controlled study 
whether teriparatide can increase the anabolic window in premenopausal women 
with lower extremity stress fractures and can hasten the healing process, as 
assessed by Magnetic Resonance Imaging (MRI). Specifically, we will evaluate: 
1) Whether bone formation markers increases more rapidly than resorption 
markers in response to daily teriparatide (20 µg) at 4 and 8 weeks and of the 
anabolic window, using the area under the curve between percent changes in 
biomarkers of formation over resorption over time, and 2) whether there is 
acceleration of the stress fracture healing, as assessed by MRI images. 
METHODS: Among 101 women screened for this study, 13 women were enrolled 
and randomized to receive teriparatide (20 µg) (n=6) or placebo (n=7) for 8 
weeks in a double-blinded trial. Lab evaluations were completed at each visit (i.e. 
baseline, 4 weeks and 8 weeks) for 25-hydroxyvitamin D (25(OH)D), serum and 
urinary calcium, PTH, thyroid-stimulating hormone (TSH), and alkaline phosphate 
as well as BTM; amino-terminal propeptide of type I collagen (P1NP) and 
osteocalcin (OC) for bone formation and serum type I collagen c-telopeptides 
(CTX) and urinary type I collagen-telopeptides for bone resorption. To assess 
fracture healing, MRI images were reviewed by a radiologist specializing in MRI 
imaging and who was blinded to the treatment interventions. MRI images were 
obtained at baseline and 8 weeks and graded on a 0 to 4 scale. Grade 4 
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represented a severe stress fracture, while Grade 0 represented a healed bone. 
Groups were compared at baseline and in terms of the changes using Wilcoxon 
rank-sum test for continuous and ranked-order data or chi square test for 
categorical test. 
RESULTS: In the teriparatide group, both formation markers were 150% above 
baseline at the end of 8 weeks and statistically significant at all time points during 
treatment. Serum P1NP levels increased steadily after administration of 
teriparatide at both 4 and 8 weeks (133.58%, p=0.003 and 179.63%, p=0.005 
respectively), and OC rapidly increased at 4 weeks (409.60%, p=0.02) and 
doubled at 8 weeks (859.13%, p=0.003). Placebo-treated participants showed a 
modest increase in bone resorption markers at 4 and 8 weeks (P1NP, 8.46% and 
15.22% respectively; OC, 20.37% and 25.85% respectively). Resorption markers 
CTX and NTX did not show any significant change during the study. Areas under 
the curve for PINP and CTX between those treated with teriparatide versus 
placebo showed a larger anabolic window in the teriparatide-treated group (m = 
145.82, ±123.03) compared to the placebo-treated group (m = 5.99, ±48.41) 
(p=0.05). According to MRI images at 8 weeks, subjects assigned teriparatide 
appeared to show some improvement in fracture healing (m = 2.17, SD±0.75) 
than did those assigned placebo (m = 1.86, SD±0.90), although these results 
were not statistically significant (p=0.31). Additionally, 3 out of 7 (42.86%) in the 
placebo group exhibited no improvement or healing of stress fractures compared 
to 1 out of 6 (16.67%) in the teriparatide group. 
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CONCLUSION: The rise in P1NP and OC markers in the teriparatide group 
represents stimulated bone formation activity, demonstrating that intermittent 
PTH has an anabolic effect on bone in premenopausal women with stress 
fractures. Resorption markers were not significantly increased in the two months 
of the study, though studies have shown that resorption markers do not respond 
to daily teriparatide treatment until after three months or more. The immediate 
and robust response in markers of bone formation, followed by a delayed 
response in bone resorption created an anabolic window, may have contributed 
to hastened bone formation (Rubin & Bilezikian, 2003). A greater percentage of 
subjects in the teriparatide group compared with the placebo group had  
improved stress fracture healing, but with a small sample size, the difference was 
not statistically significant (p= 0.31). The data from this pilot study are promising 
as they demonstrate an anabolic window using biomarkers of bone turnover in 
women with stress fractures that may, in larger clinical trials, show beneficial 
effects on acceleration of bone healing.  
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INTRODUCTION 
Stress Fractures 
Stress fractures are common injuries and they occur in approximately 10% 
of all athletes (Matheson et al., 1987; Rauh, Macera, Trone, Shaffer, & Brodine, 
2006). Stress fractures develop when excessive loads are applied to the bone 
particularly in repetitive motions and are considered one of the more severe 
overuse injuries in military recruits and civilian athletes (Rauh et al., 2006; Royer, 
Thomas, Cesini, & Legrand, 2012). Among 583,651 United States (U.S.) Army 
recruits, there were more stress fractures in women than men with 79.9 and 19.3 
cases/1,000 recruits in women and men, respectively (Knapik et al., 2012; 
Lappe, Stegman, & Recker, 2001).  Stress fractures vary according to the sport 
and intensity of physical activity (Brukner, Bradshaw, Khan, White, & Crossley, 
1996) . The most common stress fractures involve the lower extremities such as 
the tibia, metatarsals, fibula, femur, and pelvis (Rauh et al., 2006; Sallis & Jones, 
1991). These injuries can result in pain and discomfort ranging from minor 
symptoms to serious lifetime disability (Lappe et al., 2001; Matheson et al., 
1987). 
Stress fractures are diagnosed by clinical signs and symptoms. Treatment 
for stress fractures varies depending on the location and grade of the fracture. 
Low risk fractures like those involving the fibula or posterior tibia can be treated 
conservatively with ice, pain medication, a walking boot, cross training, and 
limiting high impact activities (Brewer & Gregory, 2012; Patel, Roth, & Kapil, 
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2011). Higher risk fractures like those involving the tibia and ankle should be 
treated with aggressive non-weight bearing methods, casting, and/or bone 
stimulation for extended periods (Brewer & Gregory, 2012). Pneumatic braces 
may help with the speed of healing in tibial stress fractures; however, studies 
suggest there is no additional benefit due to the discomfort and inconvenience 
(Allen et al., 2004; Moen et al., 2010; Patel et al., 2011; Swenson et al., 1997).   
Zwas et al. developed a comprehensive scintigraphic classification of 
stress fractures based on bone dimension, bone extension, and tracer 
concentration in the lesions ranging from early and mild (Grade 1) to more 
advanced and severe (Grade 4) (Zwas ST, 1987). A recent study determined that 
although bone scintigraphy may be reliable for detection of stress injuries, this 
imaging test lacks specificity (Dobrindt et al., 2012; Gaeta et al., 2005). A study 
of 50 adults with tibial stress fractures showed the sensitivity of bone 
scintigraphy, computed tomography (CT), and MRI for identification of stress 
fractures was 42%, 74%, and 88%, respectively (Gaeta et al. (2005). This study 
also showed a significant difference in early detection of stress fractures between 
MRI and both CT and bone scintigraphy (McNemar test; P < .001 and P = .008, 
respectively), demonstrating that MRI is the preferred tool to assess diagnosis of 
stress injuries and fractures (2005).  
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Figure 1. Bone Scintigraphies: Grades of Stress Fractures. Original grading system 
of stress fractures. a) Grade I: Small, ill-defined lesion in the cortical region, b) Grade II: 
Larger than grade I, well-defined, elongated lesion, c) Grade III: wide fusiform lesion with 
highly activity in the cortico-medullary region, d) Grade IV: wide extensive lesion with 
intense activity in the transcortico-medullary region. Image taken from Zwas et al., 1987 
 
 
Classification and quantification of the severity of stress fractures are 
important for providing appropriate and effective treatment recommendations 
(Fredericson, Bergman, Hoffman, & Dillingham, 1995). Griffths et al compared 
the original bone scintigraphy images with MRI findings to establish a more 
definitive grading system than what was proposed by Zwas et al (Griffiths HJ, 
1995). Fredericson et al further expanded this classification and adapted a 
methodology to identify whether any clinical symptoms may correlate with 
severity of stress injury (Fredericson et al., 1995). Grade 0 signified no 
appreciable lesions of the bone. Grade 1 and 2 indicated a mild to moderate 
periosteal edema and possible bone marrow edema, while Grade 3 and 4 
showed a moderate-to-severe edema of both the periosteum and marrow. A 
low-signal fracture line would be visible only in Grade 4 stress fractures 
(Fredericson et al., 1995). 
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Depending on the grade of the stress fracture, modified rest treatment 
may vary from 3-6 weeks for Grades 1 and 2 to 6-12 weeks for Grade 3 and 4 
(Zwas ST, 1987). In the U.S. Military, average healing for stress fractures can 
take up to 12 weeks or more with protective weight-bearing methods (Biberdorf, 
2004). Treatment period may extend beyond 12 weeks based on the physical 
activity and compliance of the patient (Lappe et al., 2001; Tuan, Wu, & Sennett, 
2004). Although the results are conflicting, some data show that modified weight-
bearing and braces may lead to a faster recovery (Allen et al., 2004; Rome, 
Handoll, & Ashford, 2005; Swenson et al., 1997). At present, there are no 
systemic pharmaceutical interventions that may improve or accelerate stress 
fracture repair.  
 
Fracture Healing 
Bone repair can be divided into 4 phases: inflammatory, soft callus 
formation, hard callus formation, and remodeling (Schindeler, McDonald, Bokko, 
& Little, 2008). The main cell types involved in the anabolic and catabolic stages 
of bone tissue are osteoblasts and osteoclasts, respectively. Osteoblasts are 
bone-forming cells involved in callus formation and in the remodeling phase of 
fracture healing (Marsh & Li, 1999). During fracture healing, osteoclasts remove 
the initial callus produced by osteoblasts and assist in further remodeling the 
cartilaginous callus into a denser form (Schindeler et al., 2008). In normal bone 
development, osteoclasts are responsible for removing calcified bone tissue and 
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creating cavities in the bone where precursors of osteoblasts line and produce 
osteoid [Figure 2] (Marsell & Einhorn, 2011). This coordinated balance between 
bone formation and resorption results in the maintenance, regeneration, and 
production of bone. Imbalances to this equilibrium may lead to a structurally 
compromised skeleton that may increase the risk of fracture (Harris & Heaney, 
1969; Seibel, 2005). 
 
 
 
       
 
 
Bone Metabolism and Turnover Assessment 
Bone is a metabolically active tissue that undergoes continuous 
remodeling through two tightly coupled mechanisms: bone formation and bone 
resorption (Seibel, 2005). Serum and urine biomarkers of bone turnover are 
available to monitor 1) bone formation with levels of amino-terminal propeptide of 
type I collagen (P1NP), osteocalcin (OC), and serum alkaline phosphatase (ALP)  
and  2) bone resorption with levels of type I collagen c-telopeptides (CTX) and n-
telopeptides (NTX) (Marcus et al., 1999; Seibel, 2005). These BTMs are used in 
some clinical situations to assess bone turnover and possible fracture risk (Ross 
Figure 2. Stages of Bone Repair. Begins with osteoclasts removing calcified bone tissue, 
then followed by osteoblasts laying out new bone. Modified from Unipath Limited, 2005. 
http://www.osteomark.com/about_osteoporosis/bone_turnover.aspx  
Osteoblasts Osteoclasts 
Cavity made by 
osteoclasts 
 
New Bone 
Formation 
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& Knowlton, 1998). These markers are widely used in research to assess bone 
remolding and provide insights into mechanisms related to the effects of 
treatment interventions on bone metabolism (NIH Consensus Development 
Panel on Osteoporosis Prevention & Therapy, 2001).  
 
  
 
 
 
 
 
 
 
 
 
 
In a cohort study of 354 postmenopausal women, data showed that 
women with rapid bone loss showed an increase in biomarkers of formation (i.e. 
ALP and OC) and resorption (i.e. free urinary deoxypyridinoline and 
pyridinolines) (Ross & Knowlton, 1998). This suggests that biomarkers of bone 
formation and resorption could provide information on bone turnover rate, which 
may also reflect bone loss rate. This acceleration in turnover, with a net increase 
Formation 
Figure 3. Bone Turnover Markers of Formation and Resorption.  
Modified from Seibel et al. Clin Biochem Rev, 2005. 
 
Figure 2 Bone Tu nover Markers 
 
Figure 3: Bone Turnover Markers of Formation and 
Resorption a) 
 
Figure 4: Bone Turnover Markers of Formation and 
Resorption a) 
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in bone resorption relative to bone formation, results in a decrease in bone mass 
and an increase in fracture risk (Misiorowski & Zgliczynski, 2012; Ross & 
Knowlton, 1998). A prospective study that included both pre- and 
postmenopausal women identified that high levels of ALP was indicative of rapid 
bone loss and was associated with lower radial bone mineral density (BMD) 
irrespective of menopausal status (Sowers, Clark, Hollis, Wallace, & Jannausch, 
1992).  
 In addition to providing insight to bone metabolism, bone biomarkers may 
also be used to monitor fracture healing. These biomarkers can vary according to 
the type and size of fracture and the amount of time it takes for the bone to repair 
(Cox, Einhorn, Tzioupis, & Giannoudis, 2010). In a study of tibial fractures, levels 
of P1NP were significantly higher at 10 weeks in non-union fractures than in well-
healed, union fractures. (Kurdy, 2000). Conversely, high levels of serum bone-
specific ALP also significantly correlated with satisfactory union of long bone 
fractures (Mukhopadhyay et al., 2011). Interpretation of these BTMs may be 
confounded due to their low specificity and presence in tissues other than bone 
(Cox et al., 2010; Seibel, 2005). Despite its variability in analysis, application of 
these biomarkers have greatly advanced the understanding of the mechanisms 
through which therapeutic interventions or diseases affect bone (Seibel, 2005). 
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Human Recombinant Parathyroid Hormone (PTH) (1-34)  
Intermittent administration of human recombinant PTH (1-34) 
(Teriparatide) is a FDA-approved anabolic treatment for patients with 
osteoporosis that stimulates bone formation (Hutton, 2003). In contrast, 
antiresorptive drugs primarily inhibit resorption and only add to the existing bone. 
Currently, teriparatide is generally used for the treatment of osteoporosis in men 
and women (E. Orwoll et al., 2000; E. S. Orwoll et al., 2003; Rubin & Bilezikian, 
2003). In a study of 101 osteoporotic, postmenopausal women, among those 
treated teriparatide [20 or 40 µg subcutaneous injection (S.Q) daily], there was 
an increase in total bone mineral content (BMC), total and cortical bone areas, 
and periosteal and endocortical circumferences in cortical bone. (Zanchetta et 
al., 2003). Compared to placebo, study subjects treated with teriparatide showed 
an enhanced mechanical strength at the distal radius, with no adverse effects on 
total BMD or cortical BMC. In addition, Neer et al. demonstrated in a study of 
1637 postmenopausal women that daily administration of teriparatide (20 or 40 
µg S.Q. daily) increased vertebral, femoral, and total body BMD (Neer et al., 
2001). These studies confirm the anabolic effects of teriparatide in the treatment 
for osteoporosis.  
The concept of PTH as an anabolic agent was originally observed during 
studies of high levels of PTH, as seen in metabolic disorders like primary 
hyperparathyroidism. The most common effect of high PTH exposure is reduced 
bone density at cortical sites such as the distal radius, which is composed of 90% 
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cortical bone (Silverberg et al., 1989). Conversely, sites of cancellous bone like 
the spine are protected in the presence of continuously elevated levels of PTH. A 
murine study revealed that when PTH is administered as a low-dose, intermittent 
agent, osteoanabolic qualities were observed (Sato, Zeng, & Turner, 1997; Tam, 
Heersche, Murray, & Parsons, 1982). Other animal studies showed that 
teriparatide increased the number of osteoblasts and osteoclasts in rabbits after 
surgical spinal fusions, and improved early callus formation and mechanical 
strength in rodents with tibial fractures (Andreassen, Ejersted, & Oxlund, 1999; 
O'Loughlin et al., 2009).  
Administration of daily teriparatide in men and women also demonstrated 
enhanced anabolic effects.  In a paired biopsy study, 16 osteoporotic men and 
women given daily teriparatide resulted in improvement in the structure of cortical 
bone and in microarchitecture of cancellous bone (Dempster et al., 2001). A 
similar study with only postmenopausal women showed compared with placebo, 
treatment with teriparatide (20 or 40 µg S.Q. daily) led to enhanced trabecular 
morphology, thickened cortical bone, and increased bone connectivity and 
volume [Figure 4] (Jiang et al., 2003).  
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Figure 4. 3D µCT Reconstructions of a Paired Iliac Crest Bone Biopsy. A) Baseline biopsy, 
treatment and B) 20 µg of teriparatide-treated bone after treatment for 21 months. Note changes 
in increase trabecular volume and connectivity and cortical thickening after therapy. Image taken 
from Jiang JBMR, 2003. 
 
 
A large, double-blind randomized trial (81% women, age range 22-89 
years old) compared the effects of teriparatide (20 µg) to alendronate (10 µg) in 
long-term glucocorticoid users (Saag et al., 2007). A greater increase in lumbar 
spine and total hip BMD was observed in those treated with teriparatide than with 
alendronate (Saag et al., 2007). Premenopausal women with glucocorticoid-
induced osteoporosis (GIO) showed similar results, suggesting that teriparatide 
improves BMD independent of gender or menopausal status (Langdahl et al., 
2009). Thus, this response to treatment implies that teriparatide counteracts the 
mechanisms by which glucocorticoids promote bone loss by directly stimulating 
bone formation (Mazziotti, Angeli, Bilezikian, Canalis, & Giustina, 2006). 
 
 
A B 
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Teriparatide and Fracture Healing 
As previously described, teriparatide improves bone structure and induces 
new bone formation. Clinical studies in humans have demonstrated that 
teriparatide produces qualitative changes in bone mineral content, structure, and 
microarchitecture (Rubin & Bilezikian, 2003; Zanchetta et al., 2003). Because of 
these anabolic features, application of teriparatide to other conditions like 
delayed or nonunion fractures is now of interest (Hodsman et al., 2005; Zhang, 
Potty, Vyas, & Lane, 2013). A placebo-controlled trial in rodents with closed 
fractures showed an increase in anabolic activity and improved mineralization 
during callus formation after daily teriparatide (40 µg) therapy (Mognetti et al., 
2011). Rodents were treated with a tetracycline fluorescent label that 
concentrated at sites of new bone formation. Following the processing of the 
bone, fluorescence intensity was quantified into luminance arbitrary units. 
Tetracycline labeling regularly increased in treated and control animals, with a 
greater increase in those treated with teriparatide. The time course for these 
changes indicated that tetracycline labeling was maximal in rodents at day 18 
and then significantly decreased from day 21 until end of observation [Figure 5].  
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Figure 5. Correlation between Daily Teriparatide and Early Callus Formation in Rodents. 
Correlation between daily administration of Teriparatide (40 µg) and callus formation in  
rodents after closed fractures. Fluorescence/area at different time points after fracture.  
(*indicates significance, * P < 0.05, **P < 0..001, ***P < 0.005). Modified from Mongetti, 2011.  
 
Anecdotal evidence on the effects of teriparatide in fracture healing are 
emerging, however, these studies are not randomized, placebo controlled trials.  
(Zhang et al., 2013). There are a number of case studies that demonstrate 
radiographic evidence of bone healing after treatment of teriparatide in subjects 
with impaired fracture healing (Raghavan & Christofides, 2012; Whyte, Mumm, & 
Deal, 2007). In a case study of a postmenopausal woman with an atypical 
femoral fracture, associated with use of a bisphosphonate, received teriparatide 
(20 µg) treatment and within one month, a radiograph showed closure of the right 
femur fracture and within three months, an increase in bone remodeling markers 
OC and CTX by 300 and 22%, respectively (Carvalho NN, 2011). 
 In order to monitor the effects of teriparatide, bone biomarkers may be 
followed as indices to bone metabolism. Serum and urine bone markers of both 
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formation and resorption increase dramatically after treatment with teriparatide 
(Hodsman et al., 2005). After a single administration, there was an immediate 
increase in resorption and inhibition of bone formation within an hour, followed by 
an increase in formation and decrease in resorption within a week (Shiraki, 
Sugimoto, & Nakamura, 2013). Teriparatide, given intermittently for a year, 
showed markers of formation peaking at 3 months and markers of resorption 
increasing within 6 months (Lane et al., 1998). As shown in Figure 6, this initial 
increase in bone formation over resorption biomarkers creates what is called an 
“anabolic window” (Bilezikian, 2008; Rubin & Bilezikian, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Anabolic Window: A Kinetic Model of Teriparatide. Anabolic Window, showing 
the difference in kinetics between markers of bone formation and bone resorption after 
months of daily administration of teriparatide. Image taken from Bilezikian, 2003. 
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Early changes in biochemical markers of formation correlate with 
improvements in BMD and bone structure (Blumsohn et al., 2011; Chen et al., 
2005). Osteoporotic women on treatment with teriparatide showed a 55% 
increase in the bone formation marker OC from baseline, whereas only a 20% 
increase occurred in the bone resorption marker NTX, forming this anabolic 
window period (Lindsay et al., 1997). When teriparatide is administered daily, a 
rapid elevation in bone formation markers that is followed by a delayed increase 
in bone resorption markers are observed (Lindsay et al., 1997). In a study of 
combined therapy of antiresorptive and anabolic treatment in postmenopausal 
women, formation marker P1NP levels increased at 1 and 6 months after 
treatment with teriparatide independent of previous types of antiresorptive 
therapy (Obermayer-Pietsch et al., 2008).  
At present, there are only two randomized-placebo controlled trials 
evaluating the effects of PTH on fracture healing in humans (Aspenberg et al., 
2010; Peichl, Holzer, Maier, & Holzer, 2011). Aspenberg et al. investigated the 
effects of teriparatide (20 or 40 µg) on acceleration of healing of distal radial 
fractures of 102 postmenopausal women (Aspenberg et al., 2010; Aspenberg & 
Johansson, 2010). Results of this study demonstrated an acceleration of fracture 
healing characterized by bridging of 3 out of 4 cortical sites in 9.1, 7.4, and 8.8 
weeks for placebo and teriparatide 20 and 40 µg, respectively [Figure 7]. Thus, 
this study demonstrated that teriparatide (20 but not 40 µg) versus placebo 
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speeded up the healing of distal radial fractures in postmenopausal women (7.4 
versus 8.8 weeks, respectively).  
 
Figure 7. Teriparatide versus Placebo in Distal Radial Fractures. Teriparatide (20 µg) 
significantly shortened median time to healing in 3 of 4 cortices and improved early callus 
formation compared to 40 µg and placebo treatment. Modified from Aspenberg, 2010. 
 
 
Very few studies examined the relationship between premenopausal 
women and teriparatide. One study compared alendronate and teriparatide in 
women with underlying conditions of GIO and low bone mass to observe which 
treatment was most effective in protecting bone loss that occurs during long-term 
glucocorticoid use (Cohen & Shane, 2008). Data showed a significant increase in 
bone formation marker P1NP from baseline at 1, 6, and 18 months and in bone 
resorption marker CTX at 6 months in premenopausal and postmenopausal 
women treated with teriparatide than alendronate (Cohen & Shane, 2008; 
Teriparatide 
(20 µg) 
Placebo 
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Sambrook, 2007). In another study, premenopausal women with endometriosis 
were randomly assigned teriparatide versus placebo for 12 months in addition to 
their nafarelin treatment, a drug used to induce estrogen deficiency in 
endometriosis and other estrogen-dependent conditions (Finkelstein et al., 1998; 
Finkelstein et al., 1994). Results showed a significantly higher increase of BTMs 
in formation and resorption in those treated with teriparatide than in those treated 
with only nafarelin (Finkelstein et al., 1998). Thus, teriparatide may be used in 
premenopausal women that are estrogen-deficient to prevent further bone loss.  
Currently, there are very few studies examining the relationship between 
teriparatide and premenopausal women. In addition, the effects of teriparatide in 
fractures healing are not well known. Due to high incidences of stress fractures in 
premenopausal women, treatment to accelerate fracture repair would advance 
their care and potentially speed up their recovery are of interest. The purpose of 
this study, therefore, is to determine the effects of teriparatide versus placebo on 
bone repair in premenopausal women with lower extremity stress fractures. The 
main endpoint of this study is to see whether teriparatide versus placebo 
increases bone formation markers in advance of resorption markers, thereby 
generating an anabolic window of bone healing. 
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OBJECTIVES 
The overall goal of this study is to examine whether compared with placebo, 
teriparatide promotes an anabolic window that may accelerate fracture repair in 
premenopausal women with lower extremity stress fractures. Specifically, this 
study will evaluate: 
 
1) Longitudinal changes in measures of bone turnover markers (BTM) of 
bone formation and resorption in placebo- and teriparatide- treated women 
at baseline and weeks 4 and 8. The BTMs will be presented as mean 
percent changes over time and as an area under the curve for the 
changes in bone formation compared with bone resorption markers; and 
This aim will test the hypothesis that compared with placebo, 
teriparatide results in an anabolic window in which there are earlier 
increases in markers of bone formation compared to resorption. 
 
2) Assessments of bone healing according to MRI. 
This aim will test whether compared with placebo, teriparatide leads 
to accelerated or improved healing of stress fractures according to 
MRI imaging at 8 weeks compared with the baseline MRI.  
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MATERIALS and METHODS 
 
Study Subjects 
Premenopausal women, between ages of 21 to 45 years old, with lower 
extremity stress fractures diagnosed within one month of a screening visit were 
eligible for enrollment in this pilot study. This randomized, double-blinded 
placebo-controlled study was conducted at the Brigham and Women’s Hospital 
(BWH), Skeletal Health and Osteoporosis Center and in the NIH-sponsored, 
Harvard Clinical and Translational Science Center (CTSC). Premenopausal 
women were eligible for this study if they had normal serum alkaline phosphatase 
and vitamin D levels and without any bone-related conditions or medications. 
Participants were excluded based on history, physical examination, or laboratory 
assessments indicating any of the following characteristics in Table 1.  
     Table 1. Study Exclusion Criteria. 
- > 3 months amenorrhea 
- Open epiphyses 
- History of x-ray radiation therapy 
- Serum alkaline phosphatase level >177 U/L 
- Serum 25-hydroxyvitamin D < 15 ng/ml 
- Pregnant or breast feeding 
- Presence of metal objects in the body (e.g. metal implants, pacemaker, 
ferromagnetic objects etc.) that are considered unsafe for MRI  
- History of a disorder/disease that is associated with low bone mass or 
fractures such as hyperthyroidism, primary hyperparathyroidism, Paget’s 
disease, hepatitis, autoimmune disease, panhypopituitarism, Ehlers-Danlos 
syndrome, Anorexia, Bulimia, Type I Diabetes, Rheumatoid Arthritis, 
osteomyelitis, hypercalciuria (urine calcium > 4mg/kg) and cancer 
- Use of medications that may affect bone mass such as Dilantin, 
Phenobarbital, bisphosphonates (within 3 years), calcitonin (within 3 
months), raloxifene, androgens, high-dose steroid use (within 3 years), and 
previous use of parathyroid hormone 
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The Partners institutional review board approved the protocol (BWH 
Protocol No. 2006P000740). All subjects provided written informed consent 
before starting any study procedure according to Good Clinical Practice. 
 
Study Drug 
  Teriparatide™ and placebo injection pens were provided by Eli Lilly 
Corporation (Indianapolis, IN, USA). Participants were randomized by the BWH 
Investigational Drug Services. Injection pens were identical in appearance and 
distributed at baseline and 4 weeks after training with the research coordinator. 
 
Study Design 
Eligible premenopausal women were enrolled and randomized to either 
teriparatide or placebo for 8 weeks. Calcium and cholecalciferol were provided to 
all subjects to achieve intakes of 1000 mg of elemental calcium and 400 IU 
vitamin D daily. Study procedures after enrollment included: reviewing medical 
history and concomitant medications with study staff, laboratory testing for serum 
electrolytes, thyroid stimulating hormone, and serum human chorionic 
gonadotropin (HCG) to exclude a pregnancy. A baseline physical examination 
was also completed. Vital signs, heights (Holtain Stadiometer, Great Britain), and 
weights were determined, and body mass index (BMI, kg/m2) was calculated. 
Laboratory tests and MRI images were performed d throughout the study as 
summarized in Table 2 below: 
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         Table 2. Study Timeline – Schedule of Participant Assessments. 
 
Procedure Baseline 
visit 
Week 
4 
Week 
8 
Physical Examination: Vital signs, 
height/weight, review diaries and adverse 
events 
   
Laboratory test for HCG, serum and 
urinary calcium, 25-hydroxyvitamin D, 
PTH, TSH, and alkaline phosphatase 
 
 
 
 
 
Laboratory test for BTMs: P1NP and OC 
(formation); NTX and CTX (resorption) 
   
MRI: Stress Fracture 
   
 
 
Biochemical markers of bone turnover were monitored at baseline, 4 
weeks, and 8 weeks in all study participants: serum N-terminal propeptide of type 
I procollagen (PINP: 19 - 83 ug/L), osteocalcin (OC: 5- 25 ng/mL), collagen type-
1 cross-linked C-telopeptide (CTX: 0.112 - 0.738 ng/mL) and urinary collagen 
type 1 cross-linked N-telopeptide (NTX: 5-65 nM BCE/mM Crea). Women had a 
urine pregnancy test at baseline, 4 and 8 weeks; all women were asked to use 
contraception; a positive pregnancy, would have excluded a woman from 
participation in this study. 
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Laboratory Assessments: 
Serum samples were collected after an overnight fast by 10am for 
markers of bone formation (e.g., P1NP and OC) and bone resorption (e.g., CTX) 
due to diurnal and biological variations of serum measures of bone turnover; a 
second morning fasting urine sample for bone resorption was obtained for NTX. 
Serum and urine samples were aliquoted and stored at -80 degree until samples 
of all time points were assayed together. 
 
Laboratory Assays:  
The P1NP level is quantified using a  radioimmunoassay (Orion 
Diagnostics, distributed by Immunodiagnostic Systems Inc. (IDS), Fountain Hills, 
AZ) and is a biomarker of osteoblast activity and bone formation This assay 
measures the N-propeptide terminal of type 1 collagen that is liberated into the 
circulation during the synthesis of type I collagen. Both the intra-assay and the 
inter-assay precision of the assay is < 5.5%. The OC level another biomarker of 
bone formation is measured by homologous equilibrium radioimmunoassay 
(ALPCO Diagnostics, Salem, NH). The intra- and inter-assay variations for these 
measures are 5.6% and 5.2% respectively. The CTX level, a test of osteoclast 
function and bone resorption, is quantified using an enzyme immunoradiometric 
assay (Nordic Bioscience, distributed by IDS, Fountain Hills, AZ). This assay 
measures C-terminal telopeptide of type I collagen, which is liberated into 
circulation during the degradation of type I collagen.  The intra-assay precision of 
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the assay is 6% and inter-assay precision is 6.5%. The urinary NTX level, 
corrected for creatinine, another biomarker of bone resorption, is determined 
using an enzyme-linked immunosorbent assay (ELISA) (Osteomark, Wampole 
Laboratories, Princeton, NJ), with intra-assay variation at 4.2-5.2% and intra-
assay precision 4.6-7.4%. All assays were done by the NIH-sponsored, Harvard 
Catalyst Central Laboratory (Boston, MA). 
 
MRI Imaging 
Upon entry to the study, all participants had a MRI at BWH to document 
the presence of a stress injury/fracture. In two instances, a MRI was accepted 
from a local facility. All MRIs were evaluated and scored for the level of stress 
fracture/injury by one radiologist who is a co-investigator on this project. A follow-
up MRI scan was conducted at 8 weeks after randomization and initiation of the 
study.  MRI scans of the stress fracture were performed on a GE Signa 1.5 Tesla 
scanner with an Excite upgrade (GE Medical Systems, Milwaukee, WI). A 
grading system for the MRI was used to assess the severity of the lower 
extremity stress fracture. Grade 4 is considered most severe and show a low-
signal fracture line, while Grade 0 signifies no appreciable bone lesions with no 
edema at the site of fracture. Fractures that demonstrate a reduction of MRI 
grade were considered to be healing.(Meyers & Wiener, 1991). Radiographs 
were assessed quantitatively by one radiologist/investigator, without knowledge 
of treatment assignment, at baseline and 8 weeks.  
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Adverse Events 
 Treatment-emergent adverse events were defined as any untoward 
medical event that occurred or worsened since baseline and these were 
collected throughout the study. Potential adverse effects that have been 
associated with teriparatide included nausea, headache, dizziness, leg cramps 
and transient increases in serum and/or urinary calcium. In addition in rodent 
models, osteosarcomas have been reported with long-term treatment.    
 
Statistical Analyses 
To address the timing hypothesis (anabolic window) in subjects 
randomized to teriparatide and placebo, the peak of P1NP and CTX for each 
study participant was determined along with the ordering of the peaks. Each 
marker will be analyzed separately. The bone turnover markers were expressed 
as mean percent changes from baseline. The percent changes in biochemical 
markers from the average baseline values and the 90% confidence intervals (CI) 
were calculated. Comparison of percent change in bone turnover markers 
between randomized treatment groups was performed using the Wilcoxon rank-
sum test for continuous variables and ranked-order data or chi square test for 
categorical results for MRI results. Statistical analysis was done with SAS 
(version 9.2). Statistical testing was performed at a two-sided significance level of 
0.05 unless otherwise noted. 
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RESULTS 
Study Subjects & Baseline Characteristics 
Data were collected from April 2009 to July 2012. As shown in Figure 8, a 
total of 101 women were screened. Of the 101 women, 54 women were enrolled 
in the study and 16 consented. One woman withdrew from the study prior to 
baseline, and two women were ineligible due to signs of fracture healing prior to 
drug assignment. A total of 14 of the 16 subjects were then randomized into two 
treatment groups: teriparatide, 20 µg (n = 6) or placebo (n=8) injections. 
However, one participant withdrew prior to Week 4 visit due to overseas travel.  
All participants had normal serum calcium levels for the duration of the 
study and HCG levels of <1 mIU/mL. No serious adverse events were reported. 
Table 3 shows the baseline characteristics. There were no differences in the 
baseline characteristics for the two groups.  
 
 Table 3. Baseline Characteristics of Study Participants (Mean ± SD) 
 
 
 
 
 
 
 
Baseline Characteristics  Teriparatide 
(20 ug) 
[n = 6] 
Placebo 
 [n =8] 
P-Value 
Age (Years) 
Weight (kg) 
Height (cm) 
Body Mass Index (kg/m2) 
Alkaline Phosphatase (U/L) 
Serum P1NP (ug/L) 
Serum OC (ng/mL) 
Serum CTX (ng/mL) 
Urinary NTX/creatinine (nM/BCE) 
32 ±5.8 
57.4 ±7.8 
160.0 ±3.6 
22.4 ±3.1 
58.3 ±19.7 
40.1 ±25.5 
5.768 ±5.0 
0.425 ±0.17 
161.67 ±132.1 
31 ±3.4 
61.8 ±13.2 
160.4 ±4.6 
24.1 ±4.9 
60.1 ±26.3 
42.5 ±11.9 
7.906 ±2.5 
0.541 ±0.32 
356.88 ±229.2 
- 
0.747 
0.846 
0.698 
0.948 
0.333 
0.432 
0.438 
0.121 
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Figure 8. Study Profile: Participant Disposition 
 
 
 
Women Screened 
[n=101] 
Women Consented  
[n=16] 
Withdrew Consent 
Prior to Baseline Visit 
[n=1];  
Ineligible for Study, 
MRI Showed Fracture 
Healing or no fracture 
[n=2] 
 
Placebo 
[n=8] 
Teriparatide 
[n=6] 
Withdrew Consent, 
Participant Travel 
Abroad [n=1] 
Placebo 
[n=7] 
 Completed Study 
[n=13] 
Baseline Visit 
[n=14] 
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Biochemical Markers  
The overall changes in biochemical markers of bone turnover from the 
beginning of therapy until 8 weeks are shown in Table 4.  
Markers of osteoblastic activity increased throughout the study (p ≤ 0.05). 
Both formation markers, P1NP and OC, were statistically significant at all time 
points. Serum P1NP levels increased steadily after administration of teriparatide 
at both 4 and 8 weeks (133.58% 51.72%, p=0.003 and 179.63% 98.80%, 
p=0.005 respectively), while OC rapidly increased at 4 weeks (409.60% 
725.90%, p=0.03) and doubled above baseline value at 8 weeks (859.13% 
1207.26%, p=0.003). At the end of treatment in those participants assigned to 
teriparatide, all bone formation markers were elevated to levels more than 150% 
of their baseline value. Placebo-treated participants showed a modest increase in 
P1NP and OC levels. Figure 9 shows the temporal response to teriparatide in 
comparison to placebo for each formation marker in mean percent changes. 
Resorption marker CTX demonstrated a modest but steady increase in 
serum levels with teriparatide (66.6% 85.78%) in comparison to placebo 
(16.27% 41.11%) (p=0.28). Urinary excretion of NTX, however, showed a 
different pattern.  NTX levels increased slightly at 4 weeks for both groups, but 
the teriparatide group fell below placebo at 8 weeks (p=0.62). By the end of 
treatment, NTX levels for teriparatide treated participants were at only 25.35% 
above baseline compared to participants treated with placebo who finished the 
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study at 54.60% 103.31% above baseline. There were no significant changes in 
resorption markers during the treatment period as shown in Figure 9.  
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The anabolic window resulting from use of teriparatide versus placebo is 
demonstrated in Figure 10 and 11. Compared with placebo-treated women, 
those who received teriparatide had a higher percentage increase in both bone 
formation PINP and bone resorption CTX markers, though not significant 
(p=0.31). Figure 11 superimposes the response of teriparatide and placebo 
between bone biomarkers P1NP and CTX over time. The area under the curve 
indicates the anabolic window. Our results show a significant increase in the area 
Figure 9. Percent Change in Bone Biomarkers in teriparatide and placebo treated 
women with stress fractures. Change in bone turnover markers (P1NP, OC, CTX, and 
NTX) in teriparatide (20 µg/d) and placebo-treated study participants in mean percent 
changes, with standard deviations. A) and B) Bone formation markers P1NP and OC, 
respectively. C) and D) Bone resorption markers: CTX and NTX, respectively. 
 
 
B) D) 
A) C)   
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Figure 10. Effects of Teriparatide versus placebo on the percent change in P1NP and CTX 
levels in premenopausal women with stress fractures.  Note: significant increase in formation 
marker P1NP in the teriparatide group compared with placebo at 4 and 8 weeks. Similar results 
were observed with bone resorption marker CTX in teriparatide versus placebo at 4 weeks. 
However, at 8 weeks, CTX showed a greater percent change than P1NP in the placebo group.  
 
Figure 11. Shaded Area under the Curve between P1NP and CTX. Comparison of the area 
under the curve for PINP and CTX between those women with stress fractures treated with 
teriparatide versus placebo. Graph shows a statistically larger area under the curve in the 
teriparatide (m=145.82, ±123.03) compared to placebo-treated women (m= 5.99, ±48.41) with 
stress fractures (p=0.05).  The shaded area between the two markers over time, under the 
curve, indicates this anabolic window.  
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under the curve in those treated with teriparatide (m = 145.82, ±123.03) versus 
those treated with placebo (m = 5.99, ±48.41) (p=0.05). 
 
MRI Imaging 
Grading system for MRI scans is shown in Table 5 according to 
Fredericson et al 1999. Chi-test showed that approximately 83.3% of women in 
the teriparatide group had healing (Grade 0) or improved fracture repair 
compared to 57.1% of women in the placebo-treated group; these changes did 
not achieve significance (p=0.31). Table 6 displays the results of MRI scans at 
baseline and at 8 weeks. Of those who did not completely heal but showed 
improvement in fracture healing, 50% were teriparatide-treated participants, while 
28.57% were placebo-treated participants. Lastly, 3 of 7 (42.86%) participants 
that received placebo exhibited no change of bone healing compared with 1 of 6 
(16.67%) that received teriparatide.  
 
  Table 5. Stress Fracture Grading System by MRI and High-Signal Short TI Inversion  
  Recovery (STIR) Images. Modified from Fredericson, 1999. 
 
Grade 0 Normal Normal 
Grade 1 
Positive STIR image 
Irregular and/or a poorly 
defined high-signal area 
Grade 2 
Positive STIR image plus 
positive T2 
Similar to grade 1, more 
intense yet still poorly 
defined 
Grade 3 
Positive T1 and T2 but 
without cortical break 
Sharply marginated high-
signal area, usually focal or 
fusiform in shape 
Grade 4 
Positive T1 and T2 fracture 
line 
Similar to grade 3 but more 
intense high signal 
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Table 6. MRI Results compared to Baseline and 8 Weeks. Grade 4 is considered a 
severe stress fracture, while Grade 0 is normal or healed bone. Reduction of grade from 
baseline to 8 weeks was considered an improvement of bone healing or healed fracture.  
No grade reduction shows no improvement or no healing.  
  
 
Subject 
 
Type of Fracture 
MRI -  
Baseline 
MRI – 
8 Weeks 
Placebo  
1 Tibia 2 2 
2 Femur 3 3 
3 Tibia 2 0 
4 Metatarsal 4 3 
5 Fibula 1 1 
6 Metatarsal 1 0 
7 Navicular 3 1 
Teriparatide 
1 Tibia 2 0 
2 Tibia (bilateral) 3 2 
3 Foot 4 2 
4 Metatarsal 4 1 
5 Femur 2 0 
6 Femur 4 4 
 
 
Adverse Effects (AE) 
There were a total of eight reports of AE. Six of the eight AE were minor 
reports of slight bruising at the injection site and were resolved in a few days. 
One subject reported a small pea-sized bump below the site of stress fracture. 
MRI imaging did not show any abnormalities. One other subject reported light-
headedness during the day that resolved within the first 4 weeks of treatment. 
Although this is listed as an adverse event, this study participant was assigned to                                                   
placebo.   
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DISCUSSION  
 This prospective, placebo-controlled study was designed to determine 
whether daily teriparatide treatment increased bone formation markers in 
advance of resorption markers in premenopausal women with lower extremity 
stress fractures resulting in an anabolic window. Our results showed that bone 
formation markers P1NP and OC significantly increased over 8 weeks of daily 
administration of teriparatide. These rises in P1NP and OC biomarkers indicate 
stimulation of bone formation activity, which supports the evidence that 
intermittent PTH has an anabolic effects on bone in women with stress fractures 
(Glover et al., 2009; Goltzman, 2008; Tam et al., 1982). This pilot study did not 
demonstrate definitively that teriparatide versus placebo resulted in accelerated 
healing of stress fractures/injuries in women over 8 weeks. Although not 
significant, our results suggest that a larger percent of women showed some 
improvement or healing of their stress fractures in the teriparatide versus 
placebo-treated women, which warrants further study in a larger clinical trial.  
 In premenopausal women with lower extremity stress fractures treated 
with teriparatide but not placebo, bone formation markers P1NP and OC 
increased rapidly at 4 weeks by 133.58% and 409.60%, respectively. This early 
increase in bone formation markers in teriparatide-treated women with stress 
fractures is similar to previous findings in postmenopausal women with 
osteopenia (Glover et al., 2009). These findings suggest enhanced anabolic 
activity, which has been associated with increased BMD and enhanced bone 
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strength in postmenopausal women (Chen et al., 2007; Hodsman, Fraher, 
Ostbye, Adachi, & Steer, 1993). In premenopausal women, treated with 
teriparatide (20 µg), high levels of bone formation marker P1NP correlated with 
an improvement in spine and hip BMD (Langdahl et al., 2009). Our data, 
however, showed that in teriparatide-treated women, serum levels of OC 
increased at 8 weeks up to 859.13% (p=0.003) above baseline compared with a 
large but smaller increase in P1NP levels of up to 179.63% (p=0.005). 
Nevertheless, both formation markers were 150% above baseline after 8 weeks 
in the teriparatide-treated women and statistically significant at all time points. 
These results support previous findings that P1NP and OC indicate increases in 
bone formation during daily teriparatide therapy (Seibel, 2005; Tsujimoto, Chen, 
Miyauchi, Sowa, & Krege, 2011). This rise in BTM reflects acceleration in bone 
turnover, which if the net effect is bone formation, results in increased total 
skeletal mass (Lindsay et al., 1997; McClung et al., 2005).   
 Although teriparatide has shown an effect on overall bone remodeling, 
there was no significant evidence on bone resorption markers examined in our 
study (Glover et al., 2009). This lack of response may be due to the study design 
than the efficacy of teriparatide. Typically, response in resorption markers to 
teriparatide treatment peak at six months (Lindsay et al., 1997). Since our study 
was designed to test the effects of teriparatide on bone healing in a two month 
interval, significant associations with teriparatide and markers of bone resorption 
were not observed as anticipated. 
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 A previous study showed significant increases in CTX concentration after 
six months of daily teriparatide in premenopausal women with GIO (Langdahl et 
al., 2009). CTX levels in our study showed a modest, but small increase at 8 
weeks of treatment, suggesting that if teriparatide therapy was extended beyond 
the two months of the study, CTX levels might have risen thereafter. As for NTX, 
the concentration of this bone resorption marker peaked as early as one month. 
NTX levels were elevated in both teriparatide and placebo groups at 4 weeks, 
which was then followed by a decrease in only the teriparatide group at 8 weeks. 
Our results differed from a placebo-controlled trial in osteoporotic men treated 
with teriparatide, in whom NTX levels remained elevated until 6 months and then 
declined towards baseline at 11 months (E. S. Orwoll et al., 2003). One possible 
reason for the inconsistency in our data may be that one study participant 
assigned to placebo had a high NTX at baseline and at 8 weeks (669 and 1492 
nM BCE/mM, respectively); normal premenopausal range in the absence of a 
fracture is 7 – 94 nM BCE/mM. 
 The immediate robust response to markers of bone formation as early as 
4 weeks followed by a delayed response in bone resorption reflects the anabolic 
window as described by Rubin and Bilezikian (Bilezikian, 2008; Rubin & 
Bilezikian, 2003). As shown in Figure 11, the shaded area between P1NP and 
CTX over time shows a larger anabolic window in those treated with teriparatide 
was significantly larger than those treated with placebo (p=0.05). Previous 
studies showed that administration of daily teriparatide increases bone formation 
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and improves bone microarchitecture and structure that may be helpful during 
bone repair (Dempster et al., 2001; Jobke et al., 2011).  
 At present there are few randomized placebo-controlled studies of the 
effects of PTH on healing of fracture (Aspenberg et al., 2010; Peichl et al., 2011). 
In the only placebo-controlled trial studying the effects of teriparatide on fracture 
repair, distal radius fractures in postmenopausal women were observed and had 
showed an acceleration of fracture repair in those treated with teriparatide (20 
µg) than placebo or teriparatide (40 µg) (Aspenberg et al., 2010). Because of 
these anabolic effects, daily administration of teriparatide is being experimentally 
used in non-controlled study to assist healing in delayed or non-union fractures. 
In a case study, daily teriparatide (20 µg) was used in a postmenopausal woman 
with a femoral fracture that showed no healing after a year. After treatment, 
patient showed radiographic closure of the fracture in one month and increased 
levels of OC and CTX in three months (300 and 22%, respectively) (Carvalho, 
Voss, Almeida, Salgado, & Bandeira, 2011).  
 Following a prospective study in fourteen patients with atypical femoral 
fractures, five patients that received teriparatide showed a significant increase in 
P1NP and CTX (343 and 196%, respectively) as well as a complete union 
fracture in two patients. By comparison, only one fracture healed in those who 
did not receive teriparatide (Chiang et al., 2013). In our placebo-controlled study, 
a significant rise in bone formation markers was observed. This rapid response in 
bone formation markers suggest stimulated bone remodeling, which has been 
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associated with increase remodeling sites of bone formation after administration 
of teriparatide (Ma et al., 2006). These anabolic changes on bone structure in 
effects to daily teriparatide may be conducive to enhance fracture healing.  
 To monitor fracture healing in our subjects, a grading system was used to 
assess the severity of the lower extremity stress fracture at baseline and 8 
weeks. Though not conclusive, it appears that teriparatide increased the number 
of healed participants compared to placebo. At 8 weeks, approximately 83.33% 
in the teriparatide group showed improved healing of stress fracture compared to 
57.14% in the placebo group, though results were found not significant (p=0.31). 
In seven participants treated with placebo, three participants (42.86%) showed 
no change, while only one out of six (16.67%) participants in the teriparatide-
treated group was unresponsive to treatment.  
 An important factor to consider when evaluating the progression of 
fracture healing in both groups is the grade of the stress fracture at baseline. Out 
of the six participants that were assigned teriparatide, half of these participants 
had Grade 4 stress fractures and yet our data still showed more improvement in 
fracture healing than placebo. Two of these three participants in the teriparatide-
treated group showed an improvement in fracture healing (Grade 4 to 2 and 
Grade 4 to 1). By comparison, only one subject in the placebo group with a 
Grade 4 stress fracture improved but slightly (Grade 4 to 3). Of note, the 
participant in the teriparatide group that did not show any improvement had a 
Grade 4 femoral stress fracture and continued with an aggressive exercise 
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regimen despite recommendations to modify her activity. In addition, she 
imposed dietary restrictions that may have in part delayed her fracture healing 
(Ohta-Fukushima, Mutoh, Takasugi, Iwata, & Ishii, 2002). After the study was 
completed, she continued with clinical care, received surgery for her stress 
fracture, and has healed since then.  
 Another important factor to consider is the location of the stress fracture. 
Each bone has a different biological and mechanical property that affect the 
healing of that bone (Lassus, Tulikoura, Konttinen, Salo, & Santavirta, 2002). 
Aspenberg et al. randomized trial controlled this confounding effect and only 
studied fractures of the distal radius in postmenopausal women (Aspenberg et 
al., 2010). Currently, there are no longitudinal studies that examine the effects of 
teriparatide and fracture healing in premenopausal women.  
Our study has some limitations. One primary limitation was the sample 
size of this pilot study. Despite extensive recruitment efforts, enrollment of study 
participants within acute onset of stress injury was a challenge (Patel et al., 
2011). Recruitment efforts were directed at working with several orthopedic 
surgeons, physiatrists, as well as athletic coaches. In addition we directed our 
recruitment efforts at local hospitals and private practices, neighboring colleges, 
and fitness centers. Another limitation of this study is that teriparatide is currently 
only FDA approved as a daily injection. Thus, participation in this study required 
that women self-administer the teriparatide as a daily injection, which was a 
deterrent for some women (Shiraki et al., 2013). Thus, this small sample size 
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may have led to increased variability in bone biomarker responses and limited 
the power to demonstrate a significant acceleration of bone healing in response 
to teriparatide versus placebo.  That being said, the results from this pilot study 
demonstrate an anabolic window in teriparatide- but not placebo-treated women 
with stress fractures that holds promise for future larger scale, placebo-controlled 
studies of the effects of teriparatide on bone healing.   
 
CONCLUSION 
In summary, in premenopausal women with stress fractures of the lower 
extremities treated with daily administration of teriparatide (20 µg) compared with 
placebo over 8 weeks, we observed an increase of bone formation markers 
P1NP and OC and no change in resorption markers. In addition our analyses 
demonstrate an anabolic window with an increased area under the curve for the 
changes in bone formation and bone resorption markers in women treated with 
teriparatide versus placebo. Although this study did not demonstrate a significant 
effect of teriparatide treatment on acceleration of fracture repair, there was a 
suggestion that more participants showed improvement or healing in the 
teriparatide than placebo group. Further placebo-controlled, larger sample 
studies are necessary to determine the effect of daily teriparatide on BTMs in 
premenopausal women with stress fractures.  
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